Free Trial

Relmada Therapeutics (RLMD) Stock Forecast & Price Target

+0.11 (+2.72%)
(As of 07/19/2024 ET)

Relmada Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 1 Wall Street analysts who have issued ratings for Relmada Therapeutics in the last 12 months, the stock has a consensus rating of "Strong Sell." Out of the 1 analysts, 1 has given a sell rating for RLMD.

Consensus Price Target

224.52% Upside
High Forecast$25.00
Average Forecast$13.50
Low Forecast$2.00

According to the 1 analysts' twelve-month price targets for Relmada Therapeutics, the average price target is $13.50. The highest price target for RLMD is $25.00, while the lowest price target for RLMD is $2.00. The average price target represents a forecasted upside of 224.52% from the current price of $4.16.

TypeCurrent Forecast
7/22/23 to 7/21/24
1 Month Ago
6/22/23 to 6/21/24
3 Months Ago
4/23/23 to 4/22/24
1 Year Ago
7/22/22 to 7/22/23
Consensus Rating
Strong Sell
Strong Sell
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
0 Hold rating(s)
0 Hold rating(s)
4 Hold rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$13.50$13.50$25.00$20.50
Forecasted Upside224.52% Upside369.84% Upside819.12% Upside84.43% Upside
Get Relmada Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

RLMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RLMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Relmada Therapeutics Stock vs. The Competition

TypeRelmada TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingStrong SellModerate BuyModerate Buy
Predicted Upside224.52% Upside3,283.13% Upside10.06% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/5/2024The Goldman Sachs Group
2 of 5 stars
 DowngradeNeutral ➝ Sell$3.00 ➝ $2.00-32.20%
2 of 5 stars
 Lower Target$26.00 ➝ $25.00+819.11%
1/23/2023SVB Leerink
1 of 5 stars
 Lower TargetOutperform$42.00 ➝ $10.00+126.24%
12/8/2022Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$7.00 ➝ $4.00-3.85%
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform
Subscribe to MarketBeat All Access for the recommendation accuracy rating
10/13/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:28 PM ET.

RLMD Forecast - Frequently Asked Questions

What is Relmada Therapeutics' forecast for 2024?

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Relmada Therapeutics is $13.50, with a high forecast of $25.00 and a low forecast of $2.00.

Should I buy or sell Relmada Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last year. There is currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" RLMD shares.

Does Relmada Therapeutics's stock price have much upside?

According to analysts, Relmada Therapeutics's stock has a predicted upside of 369.84% based on their 12-month stock forecasts.

Has Relmada Therapeutics been downgraded by Wall Street analysts recently?

Over the previous 90 days, Relmada Therapeutics's stock had 1 downgrade by analysts.

What analysts cover Relmada Therapeutics?

Relmada Therapeutics has been rated by research analysts at The Goldman Sachs Group in the past 90 days.

Do Wall Street analysts like Relmada Therapeutics more than its competitors?

Analysts like Relmada Therapeutics less than other "medical" companies. The consensus rating for Relmada Therapeutics is Strong Sell while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RLMD compares to other companies.

This page (NASDAQ:RLMD) was last updated on 7/21/2024 by Staff

From Our Partners